Trinity Biotech plc (NASDAQ:TRIB)’s share price was down 4.1% during trading on Wednesday . The company traded as low as $10.60 and last traded at $10.63, with a volume of 57,866 shares traded. The stock had previously closed at $11.09.

A number of equities analysts recently commented on TRIB shares. Roth Capital reiterated a “buy” rating on shares of Trinity Biotech plc in a research note on Thursday, April 21st. Zacks Investment Research upgraded shares of Trinity Biotech plc from a “sell” rating to a “hold” rating in a research note on Wednesday, June 22nd. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $18.00.

The company has a market capitalization of $246.84 million and a PE ratio of 39.70. The firm’s 50 day moving average price is $11.12 and its 200 day moving average price is $10.99.

Trinity Biotech plc (NASDAQ:TRIB) last released its quarterly earnings results on Tuesday, April 19th. The company reported $0.06 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.08 by $0.02. Equities analysts predict that Trinity Biotech plc will post $0.21 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in TRIB. Stephens Inc. AR raised its stake in Trinity Biotech plc by 4.3% in the fourth quarter. Stephens Inc. AR now owns 123,171 shares of the company’s stock worth $1,448,000 after buying an additional 5,045 shares during the last quarter. US Bancorp DE raised its stake in Trinity Biotech plc by 103.1% in the fourth quarter. US Bancorp DE now owns 238,825 shares of the company’s stock worth $2,808,000 after buying an additional 121,214 shares during the last quarter. Lapides Asset Management LLC raised its stake in Trinity Biotech plc by 50.0% in the fourth quarter. Lapides Asset Management LLC now owns 554,300 shares of the company’s stock worth $6,519,000 after buying an additional 184,800 shares during the last quarter. Royce & Associates LLC raised its stake in Trinity Biotech plc by 17.9% in the fourth quarter. Royce & Associates LLC now owns 702,598 shares of the company’s stock worth $8,263,000 after buying an additional 106,500 shares during the last quarter. Finally, Bank of Montreal Can purchased a new stake in Trinity Biotech plc during the fourth quarter worth $13,045,000.

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.